Skip to main content
SpringerLink
Log in

Incretin hormones as a target for therapy

  • Chapter
  • First Online:
Handbook of Incretin-based Therapies in Type 2 Diabetes

  • 524 Accesses

Abstract

Incretin hormones are responsible for the incretin effect, which is the amplification of insulin secretion when nutrients are taken in orally, as opposed to intravenously.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Nauck MA, Homberger E, Siegel, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63:492-498.

    Google Scholar 

  2. Knop FK, Aaboe K, Vilsboll T, Madsbad S, Holst JJ, Krarup T. Reduced Incretin effect in obese subjecst with normal glucose tolerance as compared to lean control subjects. Diabetes. 2008; 57[supplement 1]:A410.

    Google Scholar 

  3. Hansotia T, Baggio LL, Delmeire D, et al. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IVinhibitors. Diabetes. 2004;53:1326-1335.

    Google Scholar 

  4. Kuhre RE, Albrechtsen NW, Windelov JA, Svendsen B, Hartmann B, Holst JJ. GLP-1 amidation efficiency along the length of the intestine in mice, rats and pigs and in GLP-1 secreting cell lines. Peptides. 2014;55:52-7.

    Google Scholar 

  5. Svendsen B, Pedersen J, Jacob Wewer AN, et al. An analysis of co-secretion and co-expression of gut hormones from male rat proximal and distal small intestine. Endocrinology. 2015;156:847-857.

    Google Scholar 

  6. Egerod KL, Engelstoft MS, Grunddal KV, Nohr MK, Secher A, Sakata I, et al. A Major Lineage of Enteroendocrine Cells Coexpress CCK, Secretin, GIP, GLP-1, PYY, and Neurotensin but Not Somatostatin. Endocrinology. 2012;153:5782-5795.

    Google Scholar 

  7. Gribble FM. The gut endocrine system as a coordinator of postprandial nutrient homoeostasis. Proc Nutr Soc. 2012;1-7.

    Google Scholar 

  8. Takeda J, Seino Y, Tanaka K, et al. Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor. Proc Natl Acad Sci U S A. 1987;84:7005-7008.

    Google Scholar 

  9. Ugleholdt R, Poulsen ML, Holst PJ, et al. Prohormone convertase 1/3 is essential for processing of the glucose-dependent insulinotropic polypeptide precursor. J Biol Chem. 2006;281:11050-11057.

    Google Scholar 

  10. Volz A, Goke R, Lankat Buttgereit B, Fehmann HC, Bode HP, Goke B. Molecular cloning, functional expression, and signal transduction of the GIP-receptor cloned from a human insulinoma. FEBS Lett. 1995;373:23-29.

    Google Scholar 

  11. Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 2002;8:738-742.

    Google Scholar 

  12. de HJ, Rasmussen C, Coy DH, Holst JJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia. 2008;51:2263-2270.

    Google Scholar 

  13. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153-165.

    Google Scholar 

  14. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409-1439.

    Google Scholar 

  15. Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature. 1983;302:716-718.

    Google Scholar 

  16. Holst JJ, Bersani M, Johnsen AH, Kofod H, Hartmann B, Orskov C. Proglucagon processing in porcine and human pancreas. J Biol Chem. 1994;269:18827-18833.

    Google Scholar 

  17. Rouille Y, Martin S, Steiner DF. Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. J Biol Chem. 1995;270:26488-26496.

    Google Scholar 

  18. Bataille D, Blache P, Bergeron F. Endoprotease regulation of miniglucagon production. Ann N Y Acad Sci. 1996;805:1-8;Disc. 8-9.

    Google Scholar 

  19. Baldissera FG, Holst JJ, Knuhtsen S, Hilsted L, Nielsen OV. Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regul Pept. 1988;21:151-166.

    Google Scholar 

  20. Cohen MA, Ellis SM, Le Roux CW, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab. 2003;88:4696-46701.

    Google Scholar 

  21. Orskov C, Bersani M, Johnsen AH, Hojrup P, Holst JJ. Complete sequences of glucagon-like peptide-1 from human and pig small intestine. J Biol Chem. 1989;264:12826-12829.

    Google Scholar 

  22. Buhl T, Thim L, Kofod H, Orskov C, Harling H, Holst JJ. Naturally occurring products of proglucagon 111-160 in the porcine and human small intestine. J Biol Chem. 1988;263:8621-8624.

    Google Scholar 

  23. Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, O’Keefe SJ. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011;60:902-914.

    Google Scholar 

  24. Parker HE, Reimann F, Gribble FM. Molecular mechanisms underlying nutrient-stimulated incretin secretion. Expert Rev Mol Med. 2010;12:e1.

    Google Scholar 

  25. Kuhre RE, Frost CR, Svendsen B, Holst JJ. Molecular Mechanisms of Glucose-Stimulated GLP-1 Secretion From Perfused Rat Small Intestine. Diabetes. 2015;64:370-382.

    Google Scholar 

  26. Parker HE, Habib AM, Rogers GJ, Gribble FM, Reimann F. Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia. 2009;52:289-298.

    Google Scholar 

  27. Kuhre RE, Frost CR, Svendsen B, Holst JJ. Molecular mechnisms of glucose-stimulated GLP-1 secretion from perfused rat small intestine. Diabetes. 2015; 64:370-382.

    Google Scholar 

  28. Tolhurst G, Reimann F, Gribble FM. Nutritional regulation of glucagon-like peptide-1 secretion. J Physiol. 2009;587(Pt 1):27-32.

    Google Scholar 

  29. Hansen HS, Rosenkilde MM, Holst JJ, Schwartz TW. GPR119 as a fat sensor. Trends Pharmacol Sci. 2012;33:374-381.

    Google Scholar 

  30. Vilsboll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 2003;88:220-224.

    Google Scholar 

  31. Vilsboll T, Agerso H, Lauritsen T, et al. The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. Regul Pept. 2006;137:168-172.

    Google Scholar 

  32. Mentlein R. Dipeptidyl-peptidase IV(CD26)–role in the inactivation of regulatory peptides. Regul Pept. 1999;85:9-24.

    Google Scholar 

  33. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995;80:952-957.

    Google Scholar 

  34. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab. 2000;85:3575-3581.

    Google Scholar 

  35. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IVin the capillaries supplying the L cells of the porcine intestine [In Process Citation]. Endocrinology. 1999;140:5356-5363.

    Google Scholar 

  36. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol. 1996;271(3 Pt 1):E458-E464.

    Google Scholar 

  37. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IVinhibitors. Diabetologia. 2005;48:612-615.

    Google Scholar 

  38. Hjøllund KR, Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs. Diabetologia. 2011;54:2206-2208.

    Google Scholar 

  39. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent- mediated central mechanisms. Am J Physiol. 1997;273(4 Pt 1):G920-G927.

    Google Scholar 

  40. Wettergren A, Wojdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol. 1998;275(5 Pt 1):G984-G992.

    Google Scholar 

  41. Ruttimann EB, Arnold M, Hillebrand JJ, Geary N, Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology. 2009;150:1174-1181.

    Google Scholar 

  42. Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124:4473-4488.

    Google Scholar 

  43. Bak MJ, Wewer Albrechtsen NJ, Pedersen J, et al. Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies. Diabetes Obes Metab. 2014;16:1155-1164.

    Google Scholar 

  44. Deacon CF, Holst JJ. Immunoassays for the incretin hormones GIP and GLP-1. Best Pract Res Clin Endocrinol Metab. 2009;23:425-432.

    Google Scholar 

  45. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept. 2003;114:115-121.

    Google Scholar 

  46. Salehi M, Vahl TP, D’Alessio DA. Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion. J Clin Endocrinol Metab. 2008;93:4909-4916.

    Google Scholar 

  47. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46-52.

    Google Scholar 

  48. Knop FK, Aaboe K, Vilsboll T, Madsbad S, Krarup T, Holst JJ. Reduced incretin effect in obese subjects with normal glucose tolerance as compared to lean control subjects. Diabetologia.2010;51(suppl 1):S258.

    Google Scholar 

  49. Rhee NA, Ostoft SH, Holst JJ, Deacon CF, Vilsboll T, Knop FK. The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects. Eur J Endocrinol. 2014;171:353-362.

    Google Scholar 

  50. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63:492-498.

    Google Scholar 

  51. Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsboll T. Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:737-745.

    Google Scholar 

  52. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetic patients. J Clin Endocrinol Metab. 2001; 86:3717-3723.

    Google Scholar 

  53. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54:10-18.

    Google Scholar 

  54. Holst JJ, Knop FK, Vilsboll T, Krarup T, Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care. 2011;34 (suppl 2):S251-S257.

    Google Scholar 

  55. Rask E, Olsson T, Soderberg S, Johnson O, Seckl J, Holst JJ, et al. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care. 2001;24:1640-1645.

    Google Scholar 

  56. Calanna S, Christensen M, Holst JJ, et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia. 2013;56:965-972.

    Google Scholar 

  57. Migoya EM, Miller J, Larson P, et al. Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active FGLP-1 concentrations. Diabetes. 2007; 56(suppl 1):A74.

    Google Scholar 

  58. Faerch K, Torekov SS, Vistisen D, et al. Glucagon-like peptide-1 (GLP-1) response to oral glucose is reduced in pre-diabetes, screen-detected type 2 diabetes and obesity, and influenced by sex: The ADDITION-PRO Study. Diabetes. 2015;64:2513-2525.

    Google Scholar 

  59. Hojberg PV, Vilsboll T, Rabol R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2009;52:199-207.

    Google Scholar 

  60. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia. 2002;45:1111-1119.

    Google Scholar 

  61. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon- like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741-744.

    Google Scholar 

  62. Rachman J, Barrow BA, Levy JC, Turner RC. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia. 1997;40:205-211.

    Google Scholar 

  63. Jensen DH, Aaboe K, Henriksen JE, et al. Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes. Diabetologia. 2012;55:1406-1416.

    Google Scholar 

  64. Vilsboll T, Knop FK, Krarup T, et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab. 2003;88:4897-4903.

    Google Scholar 

  65. Toft-Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab. 2001;86:3853-3860.

    Google Scholar 

  66. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824-830.

    Google Scholar 

  67. Henry RR, Rosenstock J, Logan D, Alessi T, Luskey K, Baron MA. Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. J Diabetes Complications. 2014;28:393-398.

    Google Scholar 

  68. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. Dipeptidyl peptidase IVresistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia. 1998;41:271-278.

    Google Scholar 

  69. Raufman JP, Singh L, Singh G, Eng J. Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4. J Biol Chem. 1992;267:21432-21437.

    Google Scholar 

  70. Chen YE, Drucker DJ. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem. 1997;272:4108-4115.

    Google Scholar 

  71. Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab. 2001;281:E155-E161.

    Google Scholar 

  72. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24:275-286.

    Google Scholar 

  73. Fineman MS, Mace KF, Diamant M, et al. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab. 2012;14:546-554.

    Google Scholar 

  74. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372:1240-1250.

    Google Scholar 

  75. Schmidt LJ, Habacher W, Augustin T, Krahulec E, Semlitsch T. A systematic review and meta-analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes. Diabetes Obes Metab. 2014;16:769-779.

    Google Scholar 

  76. Gough SC. Liraglutide: from clinical trials to clinical practice. Diabetes Obes Metab. 2012;14(suppl 2):33-40.

    Google Scholar 

  77. Baggio LL, Huang Q, Brown TJ, Drucker DJ. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes. 2004;53:2492-2500.

    Google Scholar 

  78. Thompson AM, Trujillo JM. Dulaglutide: The newest GLP-1 receptor agonist for the management of type 2 diabetes. Ann Pharmacother. 2015 Jan 6.

    Google Scholar 

  79. Marguet D, Baggio L, Kobayashi T, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A. 2000;97:6874-6879.

    Google Scholar 

  80. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44:1126-1131.

    Google Scholar 

  81. Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IVinhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes. 1998;47:764-769.

    Google Scholar 

  82. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IVinhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2874-2880.

    Google Scholar 

  83. Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother. 2013;14:2047-2058.

    Google Scholar 

  84. Aaboe K, Knop FK, Vilsboll T, et al. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2010;12:323-333.

    Google Scholar 

  85. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IVinhibitor, improves model-assessed {beta}-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:4888-4894.

    Google Scholar 

  86. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IVsuppresses meal-induced incretin secretion in dogs. J Endocrinol. 2002;172:355-362.

    Google Scholar 

  87. Vardarli I, Arndt E, Deacon CF, Holst JJ, Nauck MA. Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and “isoglycemic” intravenous glucose. Diabetes. 2014;63:663-674.

    Google Scholar 

  88. Hansen L, Hartmann B, Bisgaard T, Mineo H, Jørgensen PN, Holst JJ. Somatostatin restrains the secretion of glucagon-like peptide-1 and 2 from isolated perfused porcine ileum. Am J Physiol. 2000;278:E1010-E1018.

    Google Scholar 

  89. Trebbien R, Klarskov L, Olesen M, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs. Am J Physiol Endocrinol Metab. 2004;287:E431-E438.

    Google Scholar 

  90. Muscelli E, Casolaro A, Gastaldelli A, Mari A, Seghieri G, Astiarraga B, et al. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab. 2012;97:2818-2826.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Copenhagen, Copenhagen, Denmark

    Jens Juul Holst

Authors
  1. Jens Juul Holst
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Oxford Ctre for Diabe, Endocrngy & Metab, Oxford University, Oxford, Oxfordshire, United Kingdom

    Stephen Gough

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Holst, J.J. (2016). Incretin hormones as a target for therapy. In: Gough, S. (eds) Handbook of Incretin-based Therapies in Type 2 Diabetes. Adis, Cham. https://doi.org/10.1007/978-3-319-08982-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-08982-9_2

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-08981-2

  • Online ISBN: 978-3-319-08982-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation